Navigation Links
Omeros to Present at the BioCentury NewsMakers Conference
Date:10/15/2010

SEATTLE, Oct. 15 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on October 22, 2010 at 1:30 p.m. Eastern time in New York City. The presentation will be webcast. The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- LumiThera Inc., a developmental stage medical device company ... disorders and disease, announced today that they were ... Life Sciences Discovery Fund (LSDF) commercialization grant. LumiThera was ... grants worth $500,000 to provide for commercialization activities ... macular degeneration (AMD). LSDF executive ...
(Date:5/27/2015)... WORTH, Texas , May 27, 2015 ... defines and segments the concerned market with analysis and ... $1,017.8 million by 2019 and is estimated to grow ... 2019. Browse through the TOC of the ... idea of the in-depth analysis provided. This report also ...
(Date:5/27/2015)... 27, 2015 ... décalage horaire. Il nuit sérieusement à la ... durant les réunions de mi-journée et vous ... mauvais moment dans votre chambre d,hôtel. Même ... horaire risque de vous empêcher de tenir ...
Breaking Medicine Technology:LumiThera Receives LSDF Commercialization Grant Award 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 2HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 3HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 4
... , BOCA RATON, Fla., Nov. 18 Lexington ... of just 14 leading manufacturing exporting companies nationwide to receive ... and subsequent contributions to the U.S. economy. , Presented to ... month by U.S. Secretary of Commerce, Gary Locke and Florida ...
... Korea, Nov. 18 Dong-A Pharmaceutical Co., Ltd. and ... completed a 240 patient once-a-day dosing clinical study of ... inhibitor for erectile dysfunction (ED). The multi-center study ... designed to investigate the efficacy and safety of udenafil ...
Cached Medicine Technology:Lexington International, LLC Receives 2009 U.S. President's 'E' Award Recognizing its Export Achievements 2Lexington International, LLC Receives 2009 U.S. President's 'E' Award Recognizing its Export Achievements 3Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results 2Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results 3
(Date:5/27/2015)... 27, 2015 Ticket Down is a reputable source ... Chicago Blackhawks are currently in the middle of their series against ... the series. If the Blackhawks can win tonight at home, ... on Saturday, May 30th at the Honda Center in Anaheim. ... record in the Western Conference as they won the Pacific Division ...
(Date:5/27/2015)... May 27, 2015 As the U.S. ... buy health insurance under the Affordable Care Act (ACA), ... of Public Health, the RAND Corporation and Express Scripts ... over a million initial enrollees. , The analysis ... Health Affairs and will also appear in the journal’s ...
(Date:5/27/2015)... 2015 Khanna Vision Institute (KVI) announced the ... focussed on keratoconus eye disease . Keratoconus is commonly ... its onset in the teenage years. It worsens over the ... front clear part of the eye is defective. It becomes ... It results in poor vision which cannot even be corrected ...
(Date:5/27/2015)... “We are honored to receive this gift from ... vice president of clinical affairs for SSCHC. “The increase ... provide comprehensive care to more individuals and improve the ... care and behavioral health services for Milwaukee’s vulnerable population ... whom took advantage of the clinic’s behavioral health services. ...
(Date:5/27/2015)... 2015 Hundreds of Risperdal lawsuits ... individuals who allegedly suffered gynecomastia (male breast growth) ... the antipsychotic drug continue to move forward in ... Philadelphia Court of Common Pleas. According to court ... trial program, as the third trial involving Risperdal’s ...
Breaking Medicine News(10 mins):Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 2Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 3Health News:Large-Scale Analysis of Medication Data Provides Insights into Who Is Covered by Affordable Care Act 4Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Sixteenth Street Community Health Centers To Expand Primary Care and Behavioral Health Services Through $1 Million Grant From Aurora's Better Together Fund 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3
... , EMERYVILLE, Calif., Sept. 3 Bionovo, Inc. ... results from the phase 2 clinical trial of their lead drug candidate ... European Society for Gynecology (EGS) in Rome, Italy. , ... evaluate the safety and efficacy of two doses of Menerba versus placebo. ...
... , , , ... ISIS ), the leader in antisense therapeutics, today announced that management ... Conference on Wednesday, September 9, 2009, at 11:30 a.m. ET at the ... webcast of the presentation will be available on the "Investors & Media" ...
... , , NEW YORK, Sept. ... Manhattan headquartered medical technology company testing its proprietary treatment method for ... signed a three-year lease with the option to buy on a ... plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM)) System. ...
... , ... Coker Studies Personality Traits along with Gender and Generational Differences , ... Alpharetta, GA (Vocus) September 3, 2009 ... linked to dominant personality traits? Jackson & Coker has begun a year-long research ...
... , , LOS ANGELES, ... Angeles-based manufacturer of BPA-free baby bottles that provide a safe ... chemical currently banned in Canada, Minnesota, Connecticut and under scrutiny ... California Assembly members to support the Toxics-Free Babies and ...
... , , JACKSONVILLE, Fla., Sept. 2 ... under a year by March of 2009, Linda Quirk of Run7on7.com fame ... first woman to complete the 4 Deserts - a grueling series of ... a continuation of her global efforts to raise funds and awareness for ...
Cached Medicine News:Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 3Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 4Health News:Isis Pharmaceuticals to Present at Thomas Weisel Partners' Healthcare Conference 2009 2Health News:Delcath Establishes Queensbury, NY Operations Facility 2Health News:Delcath Establishes Queensbury, NY Operations Facility 3Health News:Physicians' Personalities Provide Clues Regarding Job Satisfaction 2Health News:Physicians' Personalities Provide Clues Regarding Job Satisfaction 3Health News:Physicians' Personalities Provide Clues Regarding Job Satisfaction 4Health News:BPA-Free Baby Bottle Manufacturer Green to Grow Urges Public to Demand Support for California's Toxics-Free Babies and Toddlers Act (SB 797) 2Health News:BPA-Free Baby Bottle Manufacturer Green to Grow Urges Public to Demand Support for California's Toxics-Free Babies and Toddlers Act (SB 797) 3Health News:BPA-Free Baby Bottle Manufacturer Green to Grow Urges Public to Demand Support for California's Toxics-Free Babies and Toddlers Act (SB 797) 4Health News:56 Year-Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts(TM) in Under a Year 2Health News:56 Year-Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts(TM) in Under a Year 3
Finally, a camera that sees the way you do!,Combined with the MicroLux DVR (Digital Video Recorder), the MicroLux Headlight Camera System gives you an entirely new way to visualize, edit, share and...
... position is achieved using an increased tilt ... mobile patient bed. The patient preparation can ... In case of an emergency the patient ... room for e.g. resuscitation purposes. The integrated ...
... CXDI-50G is a one-of-kind portable Digital Radiography system ... bedside exams.,It has a 14 x 17- inch ... ,With a large imaging area and lightweight ... possible with Digital Radiography. It is large enough ...
... Bi-Ostetic is a cost-effective synthetic ... Based on Tricalcium Phosphate (TCP) and ... of human bone. BAB formulates the ... enhance bone regeneration. This formulation provides ...
Medicine Products: